CD4 and neoplasm: Very recent work has shown that treating pancreatic tumor-bearing mice with certain compounds, such as Embelin (XIAP inhibitor), can alter the tumor microenvironment by skewing CD4+ T cells away from Th17 differentiation and toward a Th1 phenotype (125).